PackTalk is a blog for the Healthcare Packaging Industry

The FDA Authorizes First COVID-19 Saliva-Based Test for Home


Published on May 20, 2020

With COVID-19 test kits in high demand, the FDA has been authorizing new at-home sample collections to help make tests more accessible.

Until this point, all at-home tests have required collection from a patient’s nose using a nasal swab and saline. But, earlier in May, the FDA approved the first COVID-19 saliva-based at home collection test by Rutgers Clinical Genomics Laboratory. This prescription-only test allows patients to collect their own sample, easily and safely, without requiring a trip to the doctor’s office.

Saliva-based testing has been found to be just as accurate, if not more so, than nasal testing and the sample is easier, safer and more comfortable to attain.

Learn more about this at home test kit here.


Comments (0)

Related Articles

Back to Basics: Your Pouch Questions Answered

April 10, 2021

Learning the steps to successfully develop a sterile barrier packaging system can be challenging. From designing, meeting regulatory requirements, to passing testing and validation, there are many important stages and stakeholders. It is daunting and complex,...

Learn More

From Machine Operator to Head of Quality

April 10, 2021

I raise up my voice—not so I can shout, but so that those without a voice can be heard. We cannot succeed if half of us are held back.

- Malala Yousafzai, recipient of the Nobel Peace Prize

The month of March is dedicated to women. As we close out Women’s...

Learn More

No Corners Cut: Vaccine Development

April 10, 2021

This week, multiple states in the USA announced an accelerated timeline for vaccine eligibility. Connecticut and Michigan are making all residents 16 and up eligible staring April 5th. President Biden has set the challenge out to every governor that every...

Learn More

Stay Informed

To stay up to date on innovative technology and products, as well as industry trends, subscribe to Oliver’s PackTalk blog below.